Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by jojomarchon Mar 07, 2018 7:02am
119 Views
Post# 27673747

Around

AroundImagine if the tables were turned around . First TLT signs a JV then  , shortly after  and because the SP exploded to $3.00  , TLT does a PP  by selling 4 million units at $2.50   ( each unit consist of one share and a half of a purchase warrant ) .

CAPITAL FUNDING

-upfront payment from JV deal                  5 - 10 million

-milestone payment for FDA approval
of Ph2 NMIBC trial                                       10 - 20 million

-PP  funding                                                  10 million

-share purchase through 
warrants exercised at 37.5 cents              3 - 4 million

-share purchase through 
warrants exercised at 54 cents                 9 - 10 million

TOTAL                                                           37 - 54 million


CAPITAL EXPENSES ( next 2 years )

-Ph2   NMIBC                                               10 - 20 million

-Ph1  LUNG                                                   5 - 10 million

-Ph1  GBM                                                    5 - 10 million

-pre clinical research                                  5 - 10 million

-salaries and other expenses                    5 - 10 million

TOTAL                                                           30 - 60 million

P.S. There is also a milestone payment of 500 - 700 million plus royalties upon FDA approval for commercialization of the drug TLD-1433 and associated treatment procedures. 


In 18 - 30 months all this could lead to a $15.00 - $40.00 SP  or a higher buyout

GO TLT GO

GO AM GO

GO JV GO

HAPPY WEDNESDAY



Bullboard Posts